Clay Siegall began his illustrious career in medical research by earning a B.S. in Zoology from the University of Maryland and a Ph.D. in Genetics from the George Washington University. Then from 1988 to 1991 he worked for the National Cancer Institute and the National Institutes of Health. From 1991 to 1997, he worked for Bristol-Myers Squibb Pharmaceutical Research Institute. In 1998, Siegall co-founded Seattle Genetics. He remains its president, CEO, and a member of its board of directors. Although as a medical researcher, he remains heavily involved in the actual discovery and development process.
However, he is also tremendously and intricately involved with the financial and business aspects. He has been instrumental in leading the company to secure over $675 million in both public and private financing. Since its founding, SG has become one of the world leaders in antibody technology. In has successfully created some of the most innovative and effective Cancer fighting antibodies in history. The company has done extremely well but has entered into several historic and life-altering partnerships with other like companies along the way, including a partnership with Genetech valued at a whopping $860 million.
Although not nearly as lucrative, several other really big partnerships have taken place with MedImmune, CuraGen, Bayer, Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute, National Institutes of Health, Alder Biopharmaceuticals, Washington Biotechnology and Biomedical Associasion, the Board of Governors of the Fred Hutchinson Cancer Research Business Alliance, and Progenics. Siegall remains extremely active in the leadership of SG. In addition, he has authored over 70 works and holds 15 patents. He also currently sits on the boards of Ultragenyx Pharmaceutical (since 2014), Mirna Therapeutics (since 2013), Inc., and Alder Biopharmaceuticals Inc. (since 2006). He remains one of the most respected members of the medical research industry and is expected to take the future to undreamed of heights.
Continue reading about Clay Siegall: